The authors proceeded to measure the therapeutic effect of anti-FITC CAR T cells in the mouse Her2-expressing breast cancer model E0771/E2 by transferring syngeneic C57BL/6-derived mouse anti-FITC CAR T cells combined with FITC-labeled trastuzumab and noted a rejection of the pre-established E0771/E2 tumor cells that was not seen in the Her2-negative parental tumor [116]. This evidence concerns the gene ERBB2 and breast carcinoma.